These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26792260)

  • 1. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
    Rovira J; Karube K; Valera A; Colomer D; Enjuanes A; Colomo L; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Delgado J; Martínez A; Villamor N; Campo E; López-Guillermo A
    Clin Cancer Res; 2016 Jun; 22(11):2755-64. PubMed ID: 26792260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 3. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
    Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
    Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Lee YS; Liu J; Fricano KA; Webb EM; Toolsie DR; Jones S; Rhoads JA; Vij R; Cashen AF; Abboud CN; Westervelt P; Bartlett NL; Dipersio JF; Kreisel FH; Lim KH
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2199-2204. PubMed ID: 28847710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
    JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
    Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYD88
    Qin Y; Qiu T; Xie Z; Chen X; Liu P; Yang J; He X; Gui L; Zhou S; Jiang H; Zhang C; Yang S; Tang L; Shi Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8483-8494. PubMed ID: 37093346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
    Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
    Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
    Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
    Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
    Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.
    Wang CZ; Lin J; Qian J; Shao R; Xue D; Qian W; Xiao GF; Deng ZQ; Yang J; Li Y; Chen XX
    Clin Biochem; 2013 Mar; 46(4-5):385-7. PubMed ID: 23178471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
    Nishimura N; Takeuchi K; Asaka R; Tuyama N; Inoue N; Kusano Y; Mishima Y; Yokoyama M; Terui Y
    Leuk Res; 2020 Oct; 97():106426. PubMed ID: 32781214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
    Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
    World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.